Related Experiment Video
Updated: Apr 23, 2026
11:03
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.9K
Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis
Martin R Turner1, Michael Benatar
1Oxford University, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, West Wing Level 3, Oxford, OX3 9DU, UK.
Muscle & Nerve
|October 8, 2014
Summary
Replicating biomarker findings for amyotrophic lateral sclerosis (ALS) is crucial for clinical translation. Understanding ALS-specific biomarker needs and cohort challenges guides future research priorities.
Area of Science:
- Neuroscience
- Biomarker Discovery
Background:
- Numerous amyotrophic lateral sclerosis (ALS) biomarkers identified lack consistent replication.
- Limited control samples hinder validation of potential ALS biomarkers.
Purpose of the Study:
- To address the critical need for validated biomarkers in amyotrophic lateral sclerosis (ALS) research.
- To highlight the unique challenges and requirements for ALS biomarker development compared to other neurodegenerative diseases.
Main Methods:
- Review of existing candidate biomarkers for amyotrophic lateral sclerosis (ALS).
- Analysis of challenges in longitudinal ALS biomarker studies.
- Discussion of strategies for advancing biomarker research.
Main Results:
- Replication of ALS biomarker results remains a significant challenge.
- The specific needs of ALS biomarker development differ from other neurodegenerative disorders.
- Longitudinal cohort studies present unique difficulties for biomarker validation.
Conclusions:
- International collaboration and multimodal approaches are essential for ALS biomarker progress.
- Integrating biomarkers into presymptomatic studies and therapeutic trials is a key priority.
- Addressing specific ALS biomarker needs is vital for clinical translation.
